On July 17, 2026, the Supreme Court of Canada released its long-awaited decision in Pharmascience Inc. v. Janssen Inc., 2026 SCC 26. In a significant ruling for pharmaceutical patentees and generic manufacturers, the Court dismissed the appeal and affirmed both the continued existence of the methods-of-medical-treatment doctrine and the validity of Janssen’s patent covering dosing...Read More